[Feasibility and radicality of PEP-chemoradiation therapy in oral squamous cell carcinoma].
From 1981 to 1987, 26 patients with oral malignancies, previously untreated squamous cell carcinomas, were treated by chemoradiation therapy, which consisted of Linac irradiation (2 Gy/d) under continuous intraarterial administration of 1.6 mg/d peplomycin (PEP). Twenty of these 26 patients did not undergo resection of the primary sites during initial hospitalization. Radicality of the PEP chemoradiation therapy was assessed after a long-term follow-up. Patients of Stage I to IV numbered 4, 7, 1 and 8, respectively. Total dosage was 60 Gy of Linac irradiation under 80-110 mg infusion of PEP. Overall CR rate and actuarial 5-year-survival rate were 75% and 63%, respectively, while these rates were 92% and 83%, respectively, for the Stage I to III cases, but 50% and 29%, respectively, for the Stage IV patients. Actuarial 5-year-survival rate of the CR Stage I to III cases was 91%, significantly higher than that of Stage IV cases (66%). We conclude the following: (1) This treatment is not indicative for patients with only a limited evaluation of PR available in the early stage of the therapeutic course. (2) Limited or uncertain response might occur in Stage IV cases. (3) The prognosis for the great majority of Stage I to III patients, however, is excellent.
Hibi
G
G
Dept. of Dent-Oral Surgery, Fujita-Gakuen Health University, School of Medicine.
Okui
K
K
Abe
A
A
Murai
T
T
Sugiura
N
N
Yamauchi
T
T
Mineno
Y
Y
Tsujikawa
T
T
Oka
T
T
D000328:Adult; D000368:Aged; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D009062:Mouth Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D017663:Peplomycin; D011379:Prognosis; D011879:Radiotherapy Dosage; D015996:Survival Rate
D001761:Bleomycin; D017663:Peplomycin